EGFR mutations

Details EGFR mutations EGFR mutations

2011-04-26

2011-04-26

Salmon, Katherine (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200, C435S287100, C436S063000, C436S064000

Reexamination Certificate

active

07932026

ABSTRACT:
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683203 (1987-07-01), Anton et al.
patent: 5679683 (1997-10-01), Bridges et al.
patent: 5869245 (1999-02-01), Yeung
patent: 2002/0102685 (2002-08-01), Sibilia et al.
patent: 2006/0147959 (2006-07-01), Bell et al.
patent: 2009/0202989 (2009-08-01), Hillan
patent: 0332435 (1989-09-01), None
patent: WO 2004/111273 (2004-12-01), None
patent: 2005/118876 (2005-12-01), None
Fuijimoto 2005 Cancer Research vol. 65 p. 11478.
Kawesha et al. International Journal of Cancer 2000 vol. 89 p. 469.
Mukohara et al. Jurnal of the national cancer institue 2005 vol. 97 p. 1185.
Thomas et al. 2004 Cancer Treatment Reviews vol. 30 p. 255.
Suzuki et al. 2003 Lung Cancer vol. 42 p. 35.
Barbacid et al. 1987 Annual Review Biochem. vol. 56 p. 779.
Pao et al. (PLOS Medicine Mar. 2005 vol. 2 p. e73) teaches.
Downward et al. (Nature Reviews Cancer Jan. 2003 vol. 3 p. 11).
Moroni et al. (The lancet May 2005 vol. 6 p. 279).
Cariello, Resolution of a Missense Mutant in Human Genomic DNA by Denaturing Gradient Fel Electrophoresis and Direct Sequencing Using in Vitro SNA Amplification: HPRTMunich, The American Society of Human Genetics, vol. 42, p. 726, 1988.
Cotton et al., “Reactivity of Cytosine and Thymine in Single-Base-Pair Mismatches with Hydroxylamine and Osmium Tetroxide and its Application to the Study of Mutations”, Proc. Natl. Acad. Sci. USA, vol. 85, 4397, 1988.
Del Tito et al, “Automated Fluorescent Analysis Procedure for Enzymatic Mutation Detection”, Clinical Chemistry 44:731-739, 1998.
Dvir, et al., “The Inhibition of EGF-dependent Proliferation of Keratinocytes by Tyrphostin Tyrosine Kinase Blockers”, J Cell Biol., 113:857-865 (1991).
Gullick, “Prevalend of Aberrant Expression of the Epidermal Growth Factor Receptor in Human Cancers”, British Medical Bulletin 1991, 47:87-98.
Han e al., “Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients Treated with Gefitinib”, Journal od Clinical Onocology, vol. 23, No. 11, p. 2493-2501, 2005.
Lei et al., “Enhancement of Chemosensitivity and Programmed Cell Death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells”, Anticancer Research 1999; 10 19:221-8.
Lynch et.al., “Activating Mutations in the epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib”, New England Journal of Medicine, vol. 350 No. 21 p. 2129-2139 (2004).
Meyers et al., “Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismataches in RNA:DNA Duplexes”, Science, vol. 230, p. 1242, 1985.
Modijtahedi and Dean, “The Receptor for RGF and its Ligands: Expression, Prognostic Value and Target for Therapy in Cancer”, International Journal of Oncology 1994, 4:277-96.
Newton et al., “Analysis of any Point Mutation in DNA. The Amplification Refractory Mutation System (ARMS)”, Nucleic Acids Research, vol. 17, p. 2503-2507, 1989.
Novack et al., “Detection of Single Base-Pair Mismatches in DNA by Chemical Modification followed by Electrophoresis in 15% Polyacrylamide Gel”, Proc. Natl. Acad. Sci. USA, vol. 83, p. 586, 1986.
Orita et al., “Rapid and Sensitive Detection of Point Mutations and DNA Polymorphisms Using the Polymerase Chain Reaction”, Genomics, vol. 5, pp. 874-879, 1989.
Orita et al., “Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms”, Proc. Natl. Acad. Sci. USA vol. 86, pp. 2766-2770, 1989.
Paez et al., “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy”, Science, vol. 304, p. 1497-1500, 2004.
Panek, et al., “In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor”, Journal of Pharmacology and Experimental Therapeutics 283, 1433-1444 (1997).
Pao et al., “EGF Receptor Gene Mutations are Common in Lung Cancers from “Never Smokers” and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib”, The Procedding of the National Academy of Sciences of the USA, vol. 101, No. 36, p. 13306-13311, 2004.
Posner et al., “Kinetic Model of the Epidermal Growth Factor (EGF) Receptor Tyrosine Kinase and a Possible Mechanism of its Activation by EGF*” J. Biol. Chem. 267 (29):20638-47 (1992).
Ruano and Kidd, “Direct Haplotyping of Chromosomal Segments from Multiple Heterozygotes Via Allele-Specific PCR Amplification”, Nucleic Acids Research, vol. 17, p. 8392, 1989.
Saiki et al., “Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase”, Science 239:487, 1988.
Salomon et al., “Epidermal Growth Factor-Related Peptides and Their Receptors in Human Malignancies”, Critical Reviews in Oncology/Hematology 1995;19:183-232.
Schaefer et al. “A Discrete Three-Amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2*”, 1999 J. Biol. Chem. 274, 859-866.
Shenk et al., “Biochemical Method for Mapping Mutational Alterations in DNA with S1 Nuclease: The Location of Deletions and Temperature-Sensitive Mutations in Simian Virus 40*”, Proc. Natl. Acad. Sci. USA, vol. 72, p. 989, 1975.
Veale et al., “The Relationship of Quantitative Epidermal Growth Factor Receptor Expression in Non-Small Cell Lung Cancer to Long Term Survival”, Br J Cancer 1993;68:162-5.
Winter et al., A Method to Detect and Characterize Point Mutations in Transcribed Genes: Amplification and Overexpression of the Mutant c-Ki-ras Allele in Human Tumor Cells:, Proc. Natl. Acad. Sci. USA, vol. 82, p. 7575, 1985.
Wu et al., “The Ligation Amplification Reaction (LAR)-Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation”, Genomics, vol. 4, pp. 560-569 (1989).
Ahrendt. S.A., et al., “Molecular Detection of Tumor Cells in Bronchoalveolar Lavage fluid from Patients with Early Stage Lung Cancer”, Journal of the National Cancer Institute. vol. 91, No. 4, pp. 332-339, (1999).
Lynch, T.J., et al., “Activating Mutations in the epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinb”. The New England Journal of Medicine, vol. 350. No. 21, pp. 2129-2139, (2004).
Miller, V.A., et al., “Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefainib Plus Carboplatin and Paclitaxel in Patients with Stage HIB or IV Non-Small-Cell Lung Cancer”, Journal of Clinical Oncology, vol. 21, No. 11, pp. 2094-2100, (2003).
Raponi et al., “KRAS mutations predict response to EGFR inhibitors,” 2008. Current Opinion in Pharmacology 8:413-418.
Van Cutsem et al., “KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSATAL experience,” 2008 ASCO Annual Meeting, Abstract No. 2.
Frykman et al., “K-ras, Cancer, EGFR Inhibitors and the FDA: Precedent-Setting ODAC Expected Mid-December” The Washington Pharma Bulletin, published Oct. 7, 2008, by the Stanford Group Company.
Amado et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal c

Affiliated with

Also associated with

Rating

EGFR mutations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EGFR mutations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EGFR mutations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2724062